Welcome to Markets Desk, your midday read on what's moving markets and why.
All eyes are turning to tomorrow's session, where Kevin Warsh, Trump's newly confirmed Fed appointee, is expected to shape the near-term conversation around monetary policy. Markets are watching closely for any signal on rate trajectory, and the timing couldn't be more sensitive given where equities are trading right now.
Shifting to energy and commodities, the interim U.S.-Iran peace agreement is proving messier in practice than in principle. Crude is beginning to move through the Strait of Hormuz again, but fertilizer shipments remain stranded, raising real concerns about agricultural input costs heading into the back half of the year. That's a story with legs well beyond the energy desk.
And in biotech, Moderna is making a significant structural bet on its own future, announcing organizational changes designed to support a wave of product launches planned for two thousand twenty seven and two thousand twenty eight. The company is explicitly positioning itself as a diversified, multi-modality platform, moving well beyond its mRNA vaccine identity. Investors will want to watch how the market prices that ambition against near-term revenue headwinds.
That's the tape. Markets Desk, signing off the floor.
